Ligand Pharmaceuticals Inc
NASDAQ:LGND
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ligand Pharmaceuticals Inc
NASDAQ:LGND
|
US |
|
E
|
EBOS Group Ltd
OTC:EBOSY
|
AU |
|
Valley National Bancorp
NASDAQ:VLY
|
US |
|
Bayerische Motoren Werke AG
XETRA:BMW
|
DE |
|
N
|
Nkt A/S
CSE:NKT
|
DK |
|
F
|
Freeport-McMoRan Inc
BMV:FCX
|
US |
Wall St Price Targets
LGND Price Targets Summary
Ligand Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for LGND is 282.65 USD with a low forecast of 249.47 USD and a high forecast of 346.5 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is LGND's stock price target?
Price Target
282.65
USD
According to Wall Street analysts, the average 1-year price target for LGND is 282.65 USD with a low forecast of 249.47 USD and a high forecast of 346.5 USD.
What is the Revenue forecast for Ligand Pharmaceuticals Inc?
Projected CAGR
17%
Over the last 14 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 3 years is 17%.
What is the Gross Profit forecast for Ligand Pharmaceuticals Inc?
Projected CAGR
20%
Over the last 14 years, the compound annual growth rate for Gross Profit has been 18%. The projected CAGR for the next 3 years is 20%.
What is the Operating Income forecast for Ligand Pharmaceuticals Inc?
Projected CAGR
80%
Over the last 14 years, the compound annual growth rate for Operating Income has been 26%. The projected CAGR for the next 3 years is 80%.
What is the Pre-Tax Income forecast for Ligand Pharmaceuticals Inc?
Projected CAGR
24%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 24%.
What is the Net Income forecast for Ligand Pharmaceuticals Inc?
Projected CAGR
30%
Over the last 14 years, the compound annual growth rate for Net Income has been 20%. The projected CAGR for the next 3 years is 30%.
